FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Investigación/Highlight the promising role of multi-receptor agonists in treating metabolic dysfunction-associated steatohepatitis and discuss their potential benefits and challenges.
Volver a Biblioteca de Investigación
GLP-1GIP/GLP-1GCGR/GLP-1

Highlight the promising role of multi-receptor agonists in treating metabolic dysfunction-associated steatohepatitis and discuss their potential benefits and challenges.

May 16, 2026
Share

Fuente del Paper

GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.

Singh Anmol et al.World journal of gastroenterology2024
Investigación Emergente

Basado en investigación emergente. Estos hallazgos son prometedores pero requieren validación adicional.

Sobre este análisis

Este artículo descompone los hallazgos del paper fuente anterior en lenguaje accesible para la comunidad de investigación de péptidos. Nuestro objetivo es destacar lo más importante — las implicaciones prácticas, la fuerza de la evidencia y lo que significa para la investigación en curso.

Multi-Receptor Agonists Show Promise in Treating Steatohepatitis: A New Era of Peptide Therapy?

Published: May 16, 2026 | Source: World journal of gastroenterology (2024) | Category: GLP-1, GIP/GLP-1, GCGR/GLP-1

Overview

A recent review published in the World Journal of Gastroenterology highlights the potential of multi-receptor agonists like GLP-1/GIP and GCGR/GLP-1 for treating metabolic dysfunction-associated steatohepatitis (MASH). This research underscores a promising new direction in peptide therapy, with these agents showing improved efficacy over single-agent therapies while also presenting unique challenges.

Study Background

Metabolic dysfunction-associated steatotic liver disease (MASLD), which includes MASH and non-alcoholic fatty liver disease (NAFLD), affects nearly one-third of the global population. The condition is linked to increased risk of metabolic, cardiovascular, and malignant diseases, making its management a pressing issue in healthcare. GLP-1 receptor agonists have been explored for their potential benefits in managing MASH, but recent studies suggest that multi-receptor agonists may offer even greater therapeutic advantages.

What the Research Found

The review synthesizes findings from various clinical trials involving GLP-1/GIP and GCGR/GLP-1 receptor agonists. These agents were found to be more effective than single-agent GLP-1 agonists in managing MASH, showing higher rates of disease resolution and fibrosis improvement. However, the tolerability of these medications remains a concern due to gastrointestinal side effects such as nausea and diarrhea.

What This Means for Peptide Users

For patients with MASH, this research suggests that multi-receptor agonists might offer better outcomes compared to traditional single-agent therapies. However, it is crucial to weigh the benefits against potential side effects and consult healthcare providers before making any changes in treatment regimens.

Limitations and Caveats

As a review paper, this study does not present new primary data but rather synthesizes existing literature. The conclusions are thus limited by the quality and availability of previous studies. Additionally, while multi-receptor agonists show promise, their long-term efficacy and safety profiles require further investigation.

How This Compares to Previous Research

Previous research has focused primarily on single-agent GLP-1 receptor agonists for MASH management, with mixed results in terms of fibrosis improvement. The current review highlights the potential benefits of multi-receptor agonists but also emphasizes ongoing challenges related to tolerability and side effects.

Our Analysis

PeptideVault's analysis suggests that while this review offers valuable insights into the evolving landscape of MASH therapeutics, it is essential to approach its conclusions with caution due to the limitations inherent in a literature-based study. Future research should aim to address these gaps by conducting more comprehensive clinical trials and long-term studies.

Key Takeaways

  • Multi-receptor agonists like GLP-1/GIP and GCGR/GLP-1 show promise for treating MASH, offering improved efficacy over single-agent therapies.
  • Gastrointestinal side effects remain a significant concern with the use of these agents.
  • Further research is needed to optimize drug regimens and identify patient populations most likely to benefit from multi-receptor agonists.

Original Source

Citation: Singh Anmol, Sohal Aalam, Batta Akash (2024). GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.. World journal of gastroenterology. DOI: 10.3748/wjg.v30.i48.5205

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue preparado por el equipo de investigación de Peptide Contacts. Se anima a los lectores a revisar la fuente completa del paper para metodología y datos completos. La publicación original está disponible en PubMed.

Investigación Relacionada

Comments

Sign in to join the discussion

Este análisis se genera a partir de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.